ARMP
Price
$1.29
Change
-$0.03 (-2.27%)
Updated
Apr 4, 04:20 PM (EDT)
Capitalization
47.76M
34 days until earnings call
MGTX
Price
$5.87
Change
-$0.26 (-4.24%)
Updated
Apr 4, 04:39 PM (EDT)
Capitalization
483.38M
34 days until earnings call
Ad is loading...

ARMP vs MGTX

Header iconARMP vs MGTX Comparison
Open Charts ARMP vs MGTXBanner chart's image
Armata Pharmaceuticals
Price$1.29
Change-$0.03 (-2.27%)
Volume$1K
Capitalization47.76M
MeiraGTx Holdings
Price$5.87
Change-$0.26 (-4.24%)
Volume$3.2K
Capitalization483.38M
ARMP vs MGTX Comparison Chart
Loading...
ARMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARMP vs. MGTX commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARMP is a Hold and MGTX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ARMP: $1.32 vs. MGTX: $6.13)
Brand notoriety: ARMP and MGTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARMP: 530% vs. MGTX: 198%
Market capitalization -- ARMP: $47.76M vs. MGTX: $483.38M
ARMP [@Biotechnology] is valued at $47.76M. MGTX’s [@Biotechnology] market capitalization is $483.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARMP’s FA Score shows that 0 FA rating(s) are green whileMGTX’s FA Score has 0 green FA rating(s).

  • ARMP’s FA Score: 0 green, 5 red.
  • MGTX’s FA Score: 0 green, 5 red.
According to our system of comparison, MGTX is a better buy in the long-term than ARMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARMP’s TA Score shows that 4 TA indicator(s) are bullish while MGTX’s TA Score has 4 bullish TA indicator(s).

  • ARMP’s TA Score: 4 bullish, 5 bearish.
  • MGTX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both ARMP and MGTX are a bad buy in the short-term.

Price Growth

ARMP (@Biotechnology) experienced а -20.00% price change this week, while MGTX (@Biotechnology) price change was -17.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.86%. For the same industry, the average monthly price growth was -16.74%, and the average quarterly price growth was -18.27%.

Reported Earning Dates

ARMP is expected to report earnings on May 08, 2025.

MGTX is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-10.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MGTX($483M) has a higher market cap than ARMP($47.8M). MGTX YTD gains are higher at: 0.657 vs. ARMP (-28.649). ARMP has higher annual earnings (EBITDA): -31.21M vs. MGTX (-121.84M). MGTX has more cash in the bank: 104M vs. ARMP (17.1M). MGTX has less debt than ARMP: MGTX (84.8M) vs ARMP (140M). MGTX has higher revenues than ARMP: MGTX (33.3M) vs ARMP (0).
ARMPMGTXARMP / MGTX
Capitalization47.8M483M10%
EBITDA-31.21M-121.84M26%
Gain YTD-28.6490.657-4,362%
P/E RatioN/AN/A-
Revenue033.3M-
Total Cash17.1M104M16%
Total Debt140M84.8M165%
FUNDAMENTALS RATINGS
ARMP vs MGTX: Fundamental Ratings
ARMP
MGTX
OUTLOOK RATING
1..100
5378
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
9443
P/E GROWTH RATING
1..100
90100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MGTX's Valuation (65) in the Biotechnology industry is in the same range as ARMP (81). This means that MGTX’s stock grew similarly to ARMP’s over the last 12 months.

MGTX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARMP (100). This means that MGTX’s stock grew similarly to ARMP’s over the last 12 months.

MGTX's SMR Rating (99) in the Biotechnology industry is in the same range as ARMP (100). This means that MGTX’s stock grew similarly to ARMP’s over the last 12 months.

MGTX's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for ARMP (94). This means that MGTX’s stock grew somewhat faster than ARMP’s over the last 12 months.

ARMP's P/E Growth Rating (90) in the Biotechnology industry is in the same range as MGTX (100). This means that ARMP’s stock grew similarly to MGTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARMPMGTX
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 18 days ago
85%
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
ARMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PBEAX22.55N/A
N/A
PGIM Jennison Value A
FMPEX26.19N/A
N/A
Fidelity Advisor Mid Cap Value C
ALSAX8.75N/A
N/A
Alger Small Cap Growth A
MFRKX55.20N/A
N/A
MFS Research R6
GIRGX21.39N/A
N/A
Goldman Sachs U.S. Equity ESG Inv